cmp target price q2 update: robust recovery across rs
Post on 12-Feb-2022
3 Views
Preview:
TRANSCRIPT
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
©
Your success is our success
Emkay
India Equity Research | Retail
October 7, 2021
Company Update
Titan Company Refer to important disclosures at the end of this report
Q2 update: Robust recovery across divisions
Titan’s Q2 business update highlights a robust recovery and a strong performance
across divisions, with the jewelry division reporting a 2-year CAGR of 32%. Network
expansion has also been accelerated during the quarter. Full unlocking and the
upcoming festive/wedding season are likely to further boost revenues in the coming
quarters and may offer more upsides, in our view. Factoring in the strong growth
momentum, we increase our FY23/FY24 EPS estimates by 8-12%. Given the solid
growth and earnings outlook, we raise our Sep’22 TP to Rs2,530 (from Rs2,000),
valuing the stock at 65x Sep’23E EPS (from 55x Sep’23E EPS earlier). Retain Buy.
Jewelry grows 78% with 2-year CAGR of 32%: Excluding bullion sales of Rs3.9bn in the
base quarter, the Jewelry segment grew 78% in Q2FY22 with a strong 2-year CAGR of
32%, aided by pent-up demand and a 10% store addition CAGR (414 jewelry stores vs.
345 in Q2FY20). Management said pent-up demand after the second wave was seen in
gift purchases, occasions, milestone buying, weddings and investments in gold. While
studded sales saw strong double-digit growth, studded mix was indicated to be lower than
pre-Covid levels due to higher growth in plain gold sales. Since Titan’s entire network of
jewelry stores across formats has been hallmarking compliant, we expect faster share
gains from unorganized players. Enrollments in the Golden Harvest Scheme (GHS)
surpassed the pre-pandemic levels. Titan also introduced digital gold for digitally-savvy
young consumers. Mandatory hallmarking is effective in 256 districts in India. Tanishq and
other jewelry brands are now 100% compliant in all aspects.
Recovery in Watches/Eyewear also ahead of expectations: Watches and Eyewear
segments also posted a strong recovery and returned to pre-Covid levels with a 2-year
revenue CAGR of -2% and 3%, respectively. A faster recovery was aided by a 2%/6%
store addition CAGR in Watches/Eyewear, improvement in mall walk-ins and consistent
growth in the e-commerce channel. Titan added 8 stores for watches and 24 for eyewear
in Q2FY22.
Caratlane’s business remained on its strong growth trajectory with 95% growth, driven by
the launch of new merchandise and marketing initiatives. Other businesses (Taneira,
Fragrances and Accessories) grew 121%, aided by higher operational stores and healthy
recovery in retail, department stores and E-commerce. TEAL recorded a 43% decline.
Q2 expectations: Based on the update, we expect TTAN to report a solid 64% revenue
growth to Rs71bn (80% excl Rs3.9bn bullion sale in Q2FY21). Despite high plain gold mix,
operating margins should reach normalized levels of 11.5%, thanks to strong cost savings
seen in Q1 and some operating leverage. We estimate a PAT of Rs5.5bn vs. Rs2bn in
Q2FY21.
Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Goods & Retail (Page 7)
Relative price chart
Source: Bloomberg This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:
Ashit Desai
ashit.desai@emkayglobal.com
+91 22 6612 1340
Devanshu Bansal
devanshu.bansal@emkayglobal.com
+91 22 6612 1385
-20
-12
-4
4
12
20
1150
1360
1570
1780
1990
2200
Oct-20Dec-20Feb-21Apr-21 Jun-21Aug-21Oct-21
%Rs
Titan Company (LHS) Rel to Nifty (RHS)
CMP Target Price
Rs 2,148 Rs 2,530 (▲) as of (October 6, 2021) 12 months
Rating Upside
BUY (■) 17.8 %
Change in Estimates
EPS Chg FY22E/FY23E (%) 3/8
Target Price change (%) 26.5
Target Period (Months) 12
Previous Reco BUY
Emkay vs Consensus
EPS Estimates
FY22E FY23E
Emkay 24.9 35.0
Consensus 21.1 28.6
Mean Consensus TP (12M) Rs 1,890
Stock Details
Bloomberg Code TTAN IN
Face Value (Rs) 1
Shares outstanding (mn) 888
52 Week H/L 2,207 / 1,154
M Cap (Rs bn/USD bn) 1,907 / 25.43
Daily Avg Volume (nos.) 12,49,860
Daily Avg Turnover (US$ mn) 31.3
Shareholding Pattern Jun '21
Promoters 52.9%
FIIs 18.4%
DIIs 9.9%
Public and Others 18.8%
Price Performance
(%) 1M 3M 6M 12M
Absolute 6 22 41 79
Rel. to Nifty 5 9 17 18
Financial Snapshot (Consolidated)
(Rs mn) FY20 FY21 FY22E FY23E FY24E
Revenue 2,10,515 2,16,440 2,88,092 3,66,974 4,26,813
EBITDA 24,666 17,240 34,438 47,368 58,022
EBITDA Margin (%) 11.7 8.0 12.0 12.9 13.6
APAT 14,927 9,740 22,090 31,088 38,653
EPS (Rs) 16.8 11.0 24.9 35.0 43.5
EPS (% chg) 1.3 (34.7) 126.8 40.7 24.3
ROE (%) 23.4 13.8 26.4 29.6 29.0
P/E (x) 127.7 195.8 86.3 61.3 49.3
EV/EBITDA (x) 77.1 108.6 54.6 39.5 31.8
P/BV (x) 28.6 25.4 20.6 16.2 12.8
Source: Company, Emkay Research
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 2
Exhibit 1: Quarterly Preview: We expect robust recovery on all fronts in Q2FY22E
Y/E, Mar (Rs. mn) 2QFY21 1QFY22 2QFY22E YoY (%) QoQ (%)
Revenue 43,180 32,490 70,703 63.7 117.6
EBITDA 2,940 1,440 8,163 177.7 466.9
EBITDA Margin, % 6.8% 4.4% 11.5% 470 710
Adjusted PAT 1,990 610 5,523 177.5 805.3
Adjusted EPS 2.2 0.7 6.2 177.5 805.3
Source: Company, Emkay Research
Exhibit 2: Key Growth assumptions (%)
Particulars FY20 FY21 FY22E FY23E FY24E
Jewellery 4.4 11.3 30.2 25.7 16.1
Watches 7.2 -39.6 57.5 36.5 13.3
Eyewear 6.4 -31.1 51.5 31.8 17.1
Caratlane 49.3 13.8 40.5 50.0 30.0
TEAL 34.2 -23.7 21.8 10.0 10.0
Source: Company, Emkay Research
Exhibit 3: Changes in estimates
Y/E, Mar (Rs. mn) FY22E FY23E FY24E
Earlier Revised % Change Earlier Revised % Change Earlier Revised % Change
Revenues 2,72,108 2,88,092 5.9 3,22,715 3,66,974 13.7 3,72,786 4,26,813 14.5
EBITDA 33,166 34,438 3.8 42,914 47,368 10.4 51,126 58,022 13.5
EBITDA Margin (%) 12.2 12.0 -20 bps 13.3 12.9 -40 bps 13.7 13.6 -10 bps
APAT 21,487 22,090 2.8 28,691 31,088 8.4 34,629 38,653 11.6
EPS (Rs) 24.2 24.9 2.8 32.3 35.0 8.4 39.0 43.5 11.6
Source: Company, Emkay Research
Exhibit 4: Titan: Growth construct of the business from demand side
CAGR (%) CAGR (%) CAGR
FY12 FY19 FY12-19 FY35E FY19-35E >FY35E
Gold Jewelry sales volume (tons) 568 604 0.9 600 (0.0) 0.0
Gold Price (Rs/10g) 25,070 28,339 1.8 86,351 7.2 5.0
Premiumisation benefit (%) 0.7 2.5 1.0
Share of organised segment (%) 26.0 32.0 3.0 48.0 2.6 1.0
Share of Titan in organized segment (%) 11.6 17.0 5.6 29.0 3.4 1.50
Titan Jewelry revenues 70,642 1,60,296 12.4 18,40,265 16.5 8.72
Jewelry segment EBIT margin (%) 9.9 12.2 3.0 13.0 0.4
Titan Jewelry EBIT 6,976 19,480 15.8 2,39,234 17.0
Titan consol revenues 89,227 1,97,785 12.0 21,19,625 16.0 8.2
Consol. EBIT margin (%) 8.8 9.2 0.7 13.0 2.2
Titan consol. EBIT 7,880 18,287 12.8 2,75,551 18.5 8.2
Source: WGC, Company, Emkay Research
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 3
Exhibit 5: Titan: Target P/E multiple derived from a two-stage dividend growth model
Revenue CAGR [FY22E-25E] (%) 19.8
EPS CAGR [FY22E-25E] (%) 27.2
Stage-1: FY25E-35E
EPS in Yr-0 [FY25E] (Rs) 51.2
EPS in Yr-1 (Rs) 59.7
EPS CAGR (%) 16.5
Years of growth [n] 10.0
RoE (%) 35.0
CoE (%) 11.10
Implied DPR (%) 53
Terminal stage: >FY35E
EPS growth (%) 8.5
RoE (%) 35.0
Implied DPR (%) 76
Fair value P/E in Mar'25E (x) 49.5
Fair value in Mar'25E (x) 2,956
Fair value in Sep'22E (x) 2,272
NPV of dividends in FY22E-25E (Rs/share) 26
Overall fair value in Sep'22E (Rs/share) 2,298
Sep'23E EPS (Rs) 39.3
Implied fair value P/E in Sep'22E (x) 58.5
Premium applied to FV (%) [a] 10.0
Implied target P/E in Sep'22E (x) 64.4
Implied TP in Sep'22E (x) 2,528
CMP (Rs/share) 2,150
Upside (%) 18
Source: Emkay Research, [a] EBIT margin expansion will likely be front-loaded than assumed
Exhibit 6: TTAN’s 1-Yr fwd PE valuation chart
Source: Company, Emkay Research
0
500
1000
1500
2000
2500
Oct-
13
Fe
b-1
4
Jun
-14
Oct-
14
Fe
b-1
5
Ju
n-1
5
Oct-
15
Fe
b-1
6
Ju
n-1
6
Oct-
16
Fe
b-1
7
Ju
n-1
7
Oct-
17
Fe
b-1
8
Ju
n-1
8
Oct-
18
Feb-1
9
Ju
n-1
9
Oct-
19
Fe
b-2
0
Ju
n-2
0
Oct-
20
Fe
b-2
1
Ju
n-2
1
Oct-
21
Titan-P/E band
35x
20x
50x
65x
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 4
Key Financials (Consolidated)
Income Statement
Y/E Mar (Rs mn) FY20 FY21 FY22E FY23E FY24E
Revenue 2,10,515 2,16,440 2,88,092 3,66,974 4,26,813
Expenditure 1,85,850 1,99,200 2,53,654 3,19,606 3,68,791
EBITDA 24,666 17,240 34,438 47,368 58,022
Depreciation 3,480 3,750 4,241 5,117 5,787
EBIT 21,186 13,490 30,197 42,250 52,235
Other Income 1,532 1,860 1,860 2,222 2,656
Interest expenses 1,662 2,030 2,446 2,811 3,115
PBT 21,057 13,320 29,612 41,661 51,776
Tax 6,090 3,530 7,442 10,473 13,022
Extraordinary Items 0 0 0 0 0
Minority Int./Income from Assoc. (40) (50) (80) (100) (100)
Reported Net Income 14,927 9,740 22,090 31,088 38,653
Adjusted PAT 14,927 9,740 22,090 31,088 38,653
Balance Sheet
Y/E Mar (Rs mn) FY20 FY21 FY22E FY23E FY24E
Equity share capital 888 888 888 888 888
Reserves & surplus 65,800 74,088 91,739 1,16,612 1,48,163
Net worth 66,688 74,976 92,627 1,17,500 1,49,051
Minority Interest 44 44 44 44 44
Loan Funds 19,658 14,210 13,407 14,118 14,628
Net deferred tax liability (1,259) (590) (356) (105) 181
Total Liabilities 85,131 88,640 1,05,722 1,31,558 1,63,905
Net block 24,864 23,730 24,189 24,272 23,685
Investment 6,127 33,030 33,041 33,041 33,041
Current Assets 1,00,067 1,03,920 1,26,137 1,68,076 2,16,184
Cash & bank balance 3,811 5,600 14 10,064 33,114
Other Current Assets 6,959 7,520 7,520 7,520 8,272
Current liabilities & Provision 47,340 73,590 79,195 95,382 1,10,555
Net current assets 52,728 30,330 46,941 72,694 1,05,629
Misc. exp 0 0 0 0 0
Total Assets 85,131 88,640 1,05,722 1,31,558 1,63,905
Cash Flow
Y/E Mar (Rs mn) FY20 FY21 FY22E FY23E FY24E
PBT (Ex-Other income) (NI+Dep) 21,017 13,270 29,532 41,561 51,676
Other Non-Cash items 0 0 0 0 0
Chg in working cap (18,456) 24,085 (21,963) (15,452) (9,599)
Operating Cashflow 540 40,390 6,813 23,565 37,957
Capital expenditure (3,027) (1,196) (2,500) (3,000) (3,000)
Free Cash Flow (2,487) 39,194 4,313 20,565 34,957
Investments (444) (26,914) 0 0 0
Other Investing Cash Flow 0 0 0 0 0
Investing Cashflow (4,885) (28,099) (2,511) (3,000) (3,000)
Equity Capital Raised 2 0 0 0 0
Loans Taken / (Repaid) 6,747 (5,594) (1,560) 0 0
Dividend paid (incl tax) (5,351) (3,551) (4,439) (6,215) (7,102)
Other Financing Cash Flow (2,244) 673 (1,443) (1,488) (1,690)
Financing Cashflow (2,508) (10,502) (9,888) (10,514) (11,908)
Net chg in cash (6,854) 1,789 (5,586) 10,050 23,050
Opening cash position 10,665 3,811 5,600 14 10,064
Closing cash position 3,811 5,600 14 10,064 33,114
Source: Company, Emkay Research
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 5
Key Ratios
Profitability (%) FY20 FY21 FY22E FY23E FY24E
EBITDA Margin 11.7 8.0 12.0 12.9 13.6
EBIT Margin 10.1 6.2 10.5 11.5 12.2
Effective Tax Rate 28.9 26.5 25.1 25.1 25.2
Net Margin 7.1 4.5 7.7 8.5 9.1
ROCE 36.0 21.9 38.4 42.4 41.1
ROE 23.4 13.8 26.4 29.6 29.0
RoIC 35.9 22.1 50.5 53.5 57.1
Per Share Data (Rs) FY20 FY21 FY22E FY23E FY24E
EPS 16.8 11.0 24.9 35.0 43.5
CEPS 20.7 15.2 29.7 40.8 50.1
BVPS 75.1 84.5 104.3 132.3 167.9
DPS 5.0 4.0 5.0 7.0 8.0
Valuations (x) FY20 FY21 FY22E FY23E FY24E
PER 127.7 195.8 86.3 61.3 49.3
P/CEPS 103.6 141.3 72.4 52.7 42.9
P/BV 28.6 25.4 20.6 16.2 12.8
EV / Sales 9.0 8.7 6.5 5.1 4.3
EV / EBITDA 77.1 108.6 54.6 39.5 31.8
Dividend Yield (%) 0.2 0.2 0.2 0.3 0.4
Gearing Ratio (x) FY20 FY21 FY22E FY23E FY24E
Net Debt/ Equity (0.1) (0.4) (0.3) (0.3) (0.4)
Net Debt/EBIDTA (0.2) (1.9) (0.8) (0.8) (1.1)
Working Cap Cycle (days) 84.8 41.7 59.5 62.3 62.0
Growth (%) FY20 FY21 FY22E FY23E FY24E
Revenue 6.4 2.8 33.1 27.4 16.3
EBITDA 23.9 (30.1) 99.8 37.5 22.5
EBIT 15.9 (36.3) 123.9 39.9 23.6
PAT 7.5 (34.7) 126.8 40.7 24.3
Quarterly (Rs mn) Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22E
Revenue 43,180 72,870 71,350 32,490 70,703
EBITDA 2,940 8,580 7,950 1,440 8,163
EBITDA Margin (%) 6.8 11.8 11.1 4.4 11.5
PAT 1,990 4,190 5,290 610 5,523
EPS (Rs) 2.2 4.7 6.0 0.7 6.2
Source: Company, Emkay Research
Shareholding Pattern (%) Jun-20 Sep-20 Dec-20 Mar-21 Jun-21
Promoters 52.9 52.9 52.9 52.9 52.9
FIIs 17.6 18.1 18.6 18.1 18.4
DIIs 10.8 11.0 10.9 11.1 9.9
Public and Others 18.7 18.1 17.6 17.9 18.8
Source: Capitaline
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 6
RECOMMENDATION HISTORY TABLE
Date Closing
Price TP
Period (months)
Rating Analyst
04-Aug-21 1,800 2,000 12m Buy Ashit Desai
07-Jul-21 1,727 1,810 12m Buy Ashit Desai
30-Apr-21 1,492 1,725 12m Buy Ashit Desai
07-Apr-21 1,514 1,650 12m Buy Ashit Desai
11-Feb-21 1,525 1,650 12m Buy Ashit Desai
07-Dec-20 1,425 1,450 12m Buy Ashit Desai
26-Nov-20 1,327 1,450 12m Buy Ashit Desai
29-Oct-20 1,178 1,300 12m Buy Ashit Desai
07-Oct-20 1,254 1,215 12m Buy Ashit Desai
11-Aug-20 1,066 1,215 12m Buy Ashit Desai
10-Jun-20 977 1,100 12m Buy Ashit Desai
14-Apr-20 967 1,100 12m Buy Ashit Desai
08-Apr-20 913 1,100 12m Buy Ashit Desai
05-Feb-20 1,280 1,240 12m Hold Ashit Desai
25-Dec-19 1,204 1,230 12m Hold Ashit Desai
06-Nov-19 1,156 1,230 12m Hold Ashit Desai
20-Sep-19 1,264 1,385 12m Buy Ashit Desai
06-Aug-19 1,047 1,150 12m Buy Ashit Desai
08-May-19 1,089 1,200 12m Buy Ashit Desai
09-Apr-19 1,099 1,080 12m Buy Ashit Desai
02-Feb-19 992 1,080 12m Buy Ashit Desai
09-Nov-18 848 1,000 12m Buy Ashit Desai
Source: Company, Emkay Research
RECOMMENDATION HISTORY CHART
Source: Bloomberg, Company, Emkay Research
740
1027
1314
1601
1888
2175
09
-Oct-
18
08
-Apr-
19
06
-Oct-
19
04
-Apr-
20
02
-Oct-
20
01
-Apr-
21
29
-Sep
-21
BUY Hold SellAccumulate Reduce PriceTarget Price
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 7
Emkay Alpha Portfolio – Consumer Goods & Retail
EAP sector portfolio
Company Name BSE200 Weight
EAP Weight
OW/UW (%)
OW/UW (bps)
EAP Weight (Normalised)
Consumer Goods & Retail 10.46 10.46 0% 0 100.00
Asian Paints 1.41 0.50 -64% -91 4.78
Berger Paints 0.19 0.00 -100% -19 0.00
Britannia Industries 0.45 0.55 23% 10 5.25
Colgate-Palmolive 0.22 0.24 9% 2 2.29
Dabur India 0.35 0.39 9% 3 3.68
Emami 0.11 0.12 2% 0 1.10
Godrej Consumer Products 0.38 0.37 -1% -1 3.58
Hindustan Unilever 2.34 1.78 -24% -55 17.06
ITC 2.02 2.09 4% 8 20.00
Marico 0.28 0.32 13% 4 3.03
Nestle India 0.68 0.42 -38% -26 4.00
Pidilite Industries 0.36 0.00 -100% -36 0.00
Radico Khaitan 0.00 0.31 NA 31 3.00
United Breweries 0.11 0.52 387% 42 5.00
United Spirits 0.00 0.31 NA 31 3.00
Varun Beverages 0.13 0.21 59% 8 2.00
ABFRL 0.07 0.10 46% 3 0.97
Jubilant FoodWorks 0.31 0.29 -7% -2 2.76
Page Industries 0.18 0.42 128% 24 4.00
Titan Company 0.88 1.05 19% 17 10.00
TCNS Clothing 0.00 0.21 NA 21 2.05
Westlife Development 0.00 0.26 NA 26 2.45
Cash 0.00 0.00 NA 0 0.00
Source: Emkay Research
* Not under coverage: Equal Weight
High Conviction/Strong Over Weight High Conviction/Strong Under Weight
Sector portfolio NAV
Base Latest
1-Apr-19 6-Oct-20 6-Apr-21 6-Jul-21 3-Sep-21 5-Oct-21
EAP - Consumer Goods & Retail 100.0 103.8 121.5 131.2 145.7 149.0
BSE200 Neutral Weighted Portfolio (ETF) 100.0 99.9 117.5 125.2 138.5 139.9
*Performance measurement base date 1st April 2019
Source: Emkay Research
Price Performance (%)
1m 3m 6m 12m
EAP - Consumer Goods & Retail 2.3% 13.5% 22.7% 43.6%
BSE200 Neutral Weighted Portfolio (ETF) 1.0% 11.7% 19.0% 40.0%
Source: Emkay Research
NAV chart
Source: Emkay Research
Please see our model portfolio (Emkay Alpha Portfolio): Nifty
Please see our model portfolio (Emkay Alpha Portfolio): SMID “Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha
Portfolios Report and is updated on regular intervals”
75
91
107
123
139
155
Apr-19 Jul-19 Nov-19 Mar-20 Jul-20 Oct-20 Feb-21 Jun-21 Sep-21
NAV
EAP - Consumer Goods & Retail BSE200 Neutral Weighted Portfolio (ETF)
Analyst: Ashit Desai
Contact Details
ashit.desai@emkayglobal.com
+91 22 6612 1340
Sector
Consumer Goods & Retail
Analyst bio
Ashit Desai holds a PGDM and FRM (US
GARP) with 13 years of research
experience on the sell side. His team
currently covers 24 stocks in the Indian
Consumer and Retail space.
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 8
Emkay Rating Distribution
Ratings Expected Return within the next 12-18 months.
BUY Over 15%
HOLD Between -5% to 15%
SELL Below -5%
Completed Date: 07 Oct 2021 05:00:01 (SGT) Dissemination Date: 07 Oct 2021 05:01:01 (SGT)
Sources for all charts and tables are Emkay Research unless otherwise specified.
GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL): Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.
This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021 | 9
ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL) The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate1 does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL. 1 An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst. 2 Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm’s length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.
COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):
Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-: 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of October 7, 2021 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced: 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research
report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL , its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s does not have any material conflict of interest in the securities recommended in this report as of October 7, 2021.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 7, 2021
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the October 7, 2021
Titan Company (TTAN IN) India Equity Research | Company Update
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.
October 7, 2021| 10
RESTRICTIONS ON DISTRIBUTION
General This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia This report is not for distribution into Australia.
Hong Kong This report is not for distribution into Hong Kong.
Indonesia This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia This report is not for distribution into Malaysia.
Singapore
This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom
This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre
This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates
This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States
DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.
Emkay Global Financial Services Ltd.
CIN - L67120MH1995PLC084899
7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com
top related